News

The evidence for U=U: why negligible risk is zero risk

 АРТ в картинках: Доступно о лечении ВИЧ (1.3 Mb) August 2017 This resource was translated into Russian by the inspirational HIV organisation ITPCru. https://itpcru.org/2017/07/23/art-v-kartinkah-dostupno-o-lechenii-vich/

IAS 2017 conference: 15 reports including new drugs… plus HIV and children, the PrEP IMPACT study in England and shortages of hepatitis vaccines in the UK…

Studies to watch and early reports from the large HIV conference in Paris…

Next generation of HIV treatments – including studies to watch for at IAS 2017…

Generic abacavir in the UK, Option B+ in Malawi, new HIV pipeline from CROI, new ARVs, selected peer review reports and more…

Also in Russian. NOTE: this links to the latest update (2021). A new i-Base resource explaining HIV and ART. Read this guide online Download ART in pictures PDF (1.3 Mb) Order print copies (free in UK) This 32-page publication explains HIV and treatment …

DHICE Project (Databases for HIV: Integration, Collaboration, Engagement) DHICE is a project to encourage collaborative working practice between different HIV cohort projects in the UK. Roy Trevelion, based at i-Base, is the Community Liaison Co-ordinator with the project. Memory works …

Reports from 23rd BHIVA conference on sexual health in the UK, and paediatric and cure-related research from CROI 2017… plus new i-Base appeal…

Pocket ART is an A7-sized guide to HIV treatment (ART). It is an easy introduction to HIV treatment. Pocket ART guide online Pocket ART guide PDF download Order a free printed copy ART stands for antiretroviral treatment. HIV drugs are …

Pocket hepatitis C (HCV) guide is a small i-Base leaflet about HCV for people who are also HIV positive. It covers testing, monitoring and treatment – especially with new HCV meds called DAAs (direct acting antivirals). Download pocket HCV – PDF (400 Kb) Order …

14 rapid reports from CROI 2017, plus journal reviews and sexual health in the UK – including drop in HIV diagnoses, PrEP news, and HPV vaccines…

Some ARVs have shown superior or non-inferior efficacy at reduced doses compared to existing recommended ones. These drugs offer improved durability and tolerability, higher bioavailability, lower pill burden, and the potential for fewer side effects. The ARVs are: dolutegravir (DTG), tenofovir alafenamide …

14 rapid reports from Seattle… new drugs, dolutegravir monotherapy studies stopped, paediatric formulations, PrEP failure case, good news from brain scans… more to follow…

Post-US election issue: reports from Glasgow Congress and Research for Preventions meetings, global treatment, EACS guidelines, UK PrEP updates and more…

Using generic PrEP bought online – new guide for how to use PrEP safely, including options for dosing…

Introduction This year the biennial Glasgow conference was held from 23-26 October 2016. The meeting has a single-track programme making it easy to attend and follow the whole programme, often highlight important European research before it is presented at CROI, …

First reports from this prevention conference being held in Chicago.

PrEP safety, side effects of integrase inhibitors, HIV and children and global access to dolutegravir – reports from four meetings + other news including reduced dose maintenance studies…

News from Durban on HIV prevention including TasP and PrEP, paediatrics, TB and cure research – plus news about PrEP in the UK…